Environmental Exposure Assessment in Breast Cancer Care

This observational study is looking at how patients and doctors feel about including environmental exposure risk assessments (EERA) in breast cancer care. This means understanding how environmental factors might affect breast cancer risk. The study aims to see if patients are interested in EERA, how they feel about getting these results, and what doctors think about using EERA in their practice. You may be able to join if you are a woman aged 18 or older, at average or high risk for breast cancer, or have early-onset breast cancer. The study plans to enroll 423 participants. The main goals are to understand patient and provider attitudes within one year.

Study design
This is an observational study with a planned enrollment of 423 participants. It is not a treatment study but rather focuses on gathering information through surveys and interviews.
What's involved
You would complete a survey (15-25 minutes) and might have an interview (30-45 minutes). Some participants might also wear Fresh Air Clip wristbands for one week.
Compensation
Not stated in the trial record.
Follow-up
Your responses will be measured for up to one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07690852

Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care

Recruiting
Not specifiedAges 18+Observational
City of Hope Medical Center
~423 participants
Updated 2026-08-31 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patient survey responses on perceived utility
Measured over Up to one year
+7 more outcomes measured
Breast Carcinoma

NCT07690852

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • City of Hope Medical Center

    Duarte, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Stacy W Gray · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

ONE of the following:
Either average risk of developing breast cancer (defined by woman with no Tyrer-Cuzick model ≥ 20%, no mention of Tyrer-Cuzick model, and no Pathogenic/Likely Pathogenic \[P/LP\] in breast cancer related genes) OR high risk of developing breast cancer (defined by ≥ 20% chance of developing breast cancer across lifetime measured by Tyrer-Cuzick model or gene mutation carrier, P/LP carrier in breast cancer related genes including BRCA1, BRCA2, BARD1, ATM, CHEK2, CDH1, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53) OR early onset breast cancer (defined by a breast cancer diagnosis in a patient younger than 50 years of age)
Age: ≥ 18 years
Speak English or Spanish
Sex: female
Willingness to:
Participate in study activities
Permit medical record/ clinical laboratory result review
Practice at COH (i.e., genetic counselors, geneticists, oncologists, nurse practitioners)
Willingness to:
Participate in study activities
Provide written consent
ONE of the following:
Either average risk of developing breast cancer (defined by woman with no Tyrer-Cuzick model ≥ 20%, no mention of Tyrer-Cuzick model, and no P/LP in breast cancer related genes) OR High risk: empirical risk of developing breast cancer (defined by ≥ 20% chance of developing breast cancer across lifetime measured by Tyrer-Cuzick model and no P/LP in breast cancer related genes) OR High Risk: gene carrier (defined by P/LP carrier in breast cancer related genes, including BRCA1, BRCA2, BARD1, ATM, CHEK2, CDH1, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53)
Age: ≥ 18 years
Speak English or Spanish
Sex: female
Willingness to:
Wear the wristband for 1 week
Participate in study activities
Permit medical record/ clinical laboratory result review
  • Patient survey responses on perceived utilityUp to one year

    Will compare emotional responses, environmental health literacy, compensatory health behaviors, and cancer fatalism across the three participant groups (average risk, high risk, and early onset) using analysis of covariance (ANCOVA). Emotional response scores will be constructed by summing items within the positive and negative subscales separately, while the environmental health literacy, compensatory health behaviors and cancer fatalism will be calculated as summed total scores. ANCOVA will be used to estimate adjusted mean differences across groups and to evaluate whether post intervention responses differ after accounting for demographic factors. Interview sessions will be audio-recorded and transcribed verbatim.

  • Patient survey responses on willingness to engageUp to one year

    Will compare emotional responses, environmental health literacy, compensatory health behaviors, and cancer fatalism across the three participant groups (average risk, high risk, and early onset) using ANCOVA. Emotional response scores will be constructed by summing items within the positive and negative subscales separately, while the environmental health literacy, compensatory health behaviors and cancer fatalism will be calculated as summed total scores. ANCOVA will be used to estimate adjusted mean differences across groups and to evaluate whether post intervention responses differ after accounting for demographic factors. Interview sessions will be audio-recorded and transcribed verbatim.

  • Patient survey responses on preferences for receiving EERA resultsUp to one year

    Will compare emotional responses, environmental health literacy, compensatory health behaviors, and cancer fatalism across the three participant groups (average risk, high risk, and early onset) using ANCOVA. Emotional response scores will be constructed by summing items within the positive and negative subscales separately, while the environmental health literacy, compensatory health behaviors and cancer fatalism will be calculated as summed total scores. ANCOVA will be used to estimate adjusted mean differences across groups and to evaluate whether post intervention responses differ after accounting for demographic factors. Interview sessions will be audio-recorded and transcribed verbatim.

  • Provider survey responses on perceived utilityUp to one year

    Descriptive analysis will be used to examine all quantitative variables.

  • Provider survey responses on feasibilityUp to one year

    Descriptive analysis will be used to examine all quantitative variables.

  • Provider survey responses on preferences for EERA disclosures into workflowsUp to one year

    Descriptive analysis will be used to examine all quantitative variables.

  • Proportion of participants who wear the work wristband for a total of 1 weekUp to one year

    Feasibility will be defined as the proportion of participants who wear the work wristband for a total of 1 week. The feasibility rate will be summarized descriptively using point estimates and 95% confidence intervals.

  • Chemical exposure measured by Fresh Air Clip wristbandUp to one year

    Acceptability will be measured in the follow-up survey using the question: "Overall, how acceptable did you find wearing the 'Fresh Air clip' wristband to measure chemical exposures in your daily life?" Participants who respond "No opinion," "Acceptable," or "Completely acceptable" will be categorized as finding the wristband acceptable. The acceptability rate will be summarized descriptively using point estimates and 95% confidence intervals.